The price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $12.49 in the last session, down -0.32% from day before closing price of $12.53. In other words, the price has decreased by -$0.04 from its previous closing price. On the day, 3992628 shares were traded.
Ratios:
We take a closer look at ARQT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.80 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 2.32 whereas as Long-Term Debt/Eq ratio is at 2.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Heron Patrick J bought 21,052 shares for $9.50 per share. The transaction valued at 199,994 led to the insider holds 8,785,284 shares of the business.
Watanabe Todd Franklin sold 14,903 shares of ARQT for $165,739 on Mar 04 ’24. The insider now owns 874,533 shares after completing the transaction at $11.12 per share. On Mar 04 ’24, another insider, Burnett Patrick, who serves as the insider of the company, sold 4,782 shares for $11.12 each. As a result, the insider received 53,182 and left with 269,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1.44B and an Enterprise Value of 1.38B. Its current Enterprise Value per Revenue stands at 23.10 whereas that against EBITDA is -6.04.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $15.40, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is 9.21, while the 200-Day Moving Average is calculated to be 6.45.
Shares Statistics:
According to the various share statistics, ARQT traded on average about 4.74M shares per day over the past 3-months and 3.2M shares per day over the past 10 days. A total of 114.97M shares are outstanding, with a floating share count of 104.94M. Insiders hold about 8.72% of the company’s shares, while institutions hold 84.25% stake in the company. Shares short for ARQT as of Mar 15, 2024 were 14.99M with a Short Ratio of 3.16, compared to 16.94M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.04% and a Short% of Float of 15.73%.
Earnings Estimates
The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.74 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$0.91, while EPS last year was -$1.31. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.63 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.21 and -$3.14 for the fiscal current year, implying an average EPS of -$2.51. EPS for the following year is -$1.46, with 6 analysts recommending between -$1.07 and -$1.95.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $13.94M. It ranges from a high estimate of $15.5M to a low estimate of $13M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $2.78M, an estimated increase of 401.30% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $21.64M, an increase of 317.00% less than the figure of $401.30% in the same quarter last year. There is a high estimate of $26.5M for the next quarter, whereas the lowest estimate is $16M.
A total of 6 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $122.5M, while the lowest revenue estimate was $75M, resulting in an average revenue estimate of $105.27M. In the same quarter a year ago, actual revenue was $59.61M, up 76.60% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $213.96M in the next fiscal year. The high estimate is $249M and the low estimate is $165M. The average revenue growth estimate for next year is up 103.20% from the average revenue estimate for this year.
